rs193922146
Positions:
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The ENST00000225964.10(COL1A1):c.2236-17C>G variant causes a splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000929 in 1,610,566 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.00089 ( 6 hom. )
Consequence
COL1A1
ENST00000225964.10 splice_polypyrimidine_tract, intron
ENST00000225964.10 splice_polypyrimidine_tract, intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.812
Genes affected
COL1A1 (HGNC:2197): (collagen type I alpha 1 chain) This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -16 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.66).
BP6
Variant 17-50190941-G-C is Benign according to our data. Variant chr17-50190941-G-C is described in ClinVar as [Likely_benign]. Clinvar id is 35909.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-50190941-G-C is described in Lovd as [Likely_benign].
BS2
High AC in GnomAd4 at 196 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL1A1 | NM_000088.4 | c.2236-17C>G | splice_polypyrimidine_tract_variant, intron_variant | ENST00000225964.10 | NP_000079.2 | |||
COL1A1 | XM_005257058.5 | c.2236-17C>G | splice_polypyrimidine_tract_variant, intron_variant | XP_005257115.2 | ||||
COL1A1 | XM_005257059.5 | c.1318-17C>G | splice_polypyrimidine_tract_variant, intron_variant | XP_005257116.2 | ||||
COL1A1 | XM_011524341.2 | c.2038-17C>G | splice_polypyrimidine_tract_variant, intron_variant | XP_011522643.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL1A1 | ENST00000225964.10 | c.2236-17C>G | splice_polypyrimidine_tract_variant, intron_variant | 1 | NM_000088.4 | ENSP00000225964 | P1 | |||
COL1A1 | ENST00000476387.1 | n.585-17C>G | splice_polypyrimidine_tract_variant, intron_variant, non_coding_transcript_variant | 2 | ||||||
COL1A1 | ENST00000494334.1 | upstream_gene_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.00129 AC: 196AN: 152086Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
196
AN:
152086
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00105 AC: 264AN: 250740Hom.: 0 AF XY: 0.000944 AC XY: 128AN XY: 135598
GnomAD3 exomes
AF:
AC:
264
AN:
250740
Hom.:
AF XY:
AC XY:
128
AN XY:
135598
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000892 AC: 1301AN: 1458480Hom.: 6 Cov.: 33 AF XY: 0.000966 AC XY: 701AN XY: 725740
GnomAD4 exome
AF:
AC:
1301
AN:
1458480
Hom.:
Cov.:
33
AF XY:
AC XY:
701
AN XY:
725740
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00129 AC: 196AN: 152086Hom.: 0 Cov.: 31 AF XY: 0.00159 AC XY: 118AN XY: 74310
GnomAD4 genome
AF:
AC:
196
AN:
152086
Hom.:
Cov.:
31
AF XY:
AC XY:
118
AN XY:
74310
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 12, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2023 | COL1A1: BS1 - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Apr 24, 2018 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 03, 2023 | Variant summary: COL1A1 c.2236-17C>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0011 in 250740 control chromosomes (gnomAD). The observed variant frequency is approximately 37 fold of the estimated maximal expected allele frequency for a pathogenic variant in COL1A1 causing Osteogenesis Imperfecta phenotype (2.8e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.2236-17C>G in individuals affected with Osteogenesis Imperfecta and no experimental evidence demonstrating its impact on protein function have been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. - |
Osteogenesis imperfecta type I Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 21, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at